MimoVax // EU Project

Project description:

Alzheimer’s disease (AD) is the most common form of dementia in humans. According to the Alzheimer Association there are currently 12 million patients worldwide with estimated social costs for each patient reaching $40,000 per year. At present, no effective treatment is available to stop the progressive neuro-degeneration and associated cognitive decline in AD patients. AD is characterised by the abnormal accumulation of amyloid plaques in the brain.
These plaques consist mainly of the Amyloid-(A) peptides Aß40/42 derived from the Amyloid Precursor Protein (APP). Immunotherapeutic treatment targeting Aß led to amyloid plaque reduction and has had beneficial impacts on disease progression in animal models. However, the first phase II clinical vaccination trial in AD patients using full length Aß42 as antigen had to be discontinued due to severe neuroinflammatory side effects including brain infiltration by autoreactive T-cells. In humans most of the amyloid plaque material is formed by N-terminally truncated and modified Aß derivatives. These truncated Aß species are correlated with an increasing severity and early onset of neurodegeneration in AD patients.
In light of the characteristics of amyloid composition in patients, these truncated Aß peptides are highly attractive targets providing neoepitopes not present on parental APP. The Mimotope technology presented in this proposal will be used to create antigens mimicking potentially pathological B-cell epitopes on truncated Aß. A Mimotope-based AD vaccine targeting truncated forms of Aß would therefore induce a safe antibody response exclusively reacting with the pathological Aß molecules but not with parental APP and would avoid the induction of autoreactive T-cells. Thus, the MimoVax vaccine will provide an innovative, safe, cost effective and efficient approach to successfully treat AD patients and to limit the severe personal and economic impact of AD on patients, their families and society.


Quick overview:

Project References: 37702
Coordinator: AFFiRiS AG, Austria
Status: Completed
Start: 01.10.2006
End: 31.12.2010
Total Cost: EUR 4,327,500
EU contribution: EUR 2,370,155


biolution contribution:

Proposal preparation: Content, Administration
Grant preparation: Contract development, Budget, Consortium Agreement
Implementation: Project Management, Dissemination

Partners / Collaborations

biolution GmbH, AT
JSW-Research GmbH, AT
piCHEM R&D – Dr. Fritz Andreae, AT
Philipp University of Marburg, DE
Technical University of Munich-Klinikum Rechts der Isar, DE
EuroEspes SA, ES

Clinical Trials Communication Consulting EU Projects FP6 ND Project Management Vaccines

Related items: